A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years. The survival for GBM has increased in the last decade but is still low with a median survival of 15-18 months. Recurrence after initial standard therapy, radiation therapy and chemotherapy with temozolomide, few options are available. Even with further therapy, median progression free survival at 6 months after first relapse (PFS-6) is only 15%. Similarly, anaplastic astrocytoma and anaplastic oligodendroglioma, grade III gliomas, once recurrent after radiation therapy and first-line chemotherapy, have identical therapeutic options and poor outcomes with PFS-6 of 31%. Temozolomide (TMZ) has a favorable side effect profile and is available orally, however, cytotoxicity occurs. Metronomic temozolomide at low doses on a continuous schedule, have demonstrated better survival in studies. This study will determine the recommended dose and the side effects of PCI-24781/Abexinostat with metronomic temozolomide.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona przez biopsję diagnoza zaawansowanego guza mózgu (stopień III lub IV)
- •Wcześniejsza radioterapia i chemioterapia Temodar
- •Wiek co najmniej 19 lat
- •Zadowalająca funkcja nerek i wątroby
- •Wystarczająca liczba komórek krwi do bezpiecznego leczenia
- •Mogą być włączeni pacjenci po poprzednich terapiach dla nawrotów choroby
- •Całkowite wyzdrowienie z działań niepożądanych poprzednich leków
- •Możliwość podpisania zgody na udział w badaniu
✗ Disqualifies
- •Choroby serca lub zaburzenia rytmu serca w ciągu ostatnich 6 miesięcy
- •Problemy zdrowotne mogące utrudnić przyjmowanie leku lub zagrażające bezpieczeństwu
- •Inne poważne choroby mogące wpłynąć na uczestnictwo w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 19 Years
- Last updated (source)
- September 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Nebraska Medical Center
Omaha, United States
Trial contact
Michaela K Savine, RN
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.